BNP Paribas Financial Markets’s Summit Therapeutics SMMT Stock Holding History

BNP Paribas Financial Markets’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.01M	Buy	274,894 +225,854	+461%	+$4.01M	﹤0.01%	2268
2026 Q1	$930K	Buy	49,040 +11,956	+32%	+$193K	﹤0.01%	3187
2025 Q4	$649K	Buy	37,084 +7,908	+27%	+$149K	﹤0.01%	3420
2025 Q3	$603K	Sell	29,176 -668	-2%	-$16.2K	﹤0.01%	3446
2025 Q2	$635K	Sell	29,844 -1,068,645	-97%	-$24.4M	﹤0.01%	3176
2025 Q1	$21.2M	Buy	1,098,489 +605,300	+123%	+$12.1M	0.01%	1013
2024 Q4	$8.8M	Buy	+493,189	New	+$9.56M	﹤0.01%	1440
2022 Q4	–	Sell	-1,159	Closed	-$1.38K	–	4546
2022 Q3	$1.38K	Buy	+1,159	New	+$1.31K	﹤0.01%	4389

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BNP Paribas Financial Markets's SMMT Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Summit Therapeutics (SMMT) stake by 461% in Q2 2026, buying an estimated $4.01M and bringing the position to 274,894 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

BNP Paribas Financial Markets first reported a position in SMMT in Q3 2022 and has held it in 8 quarters since. The position peaked at $21.2M in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

BNP Paribas Financial Markets held 274,894 shares of Summit Therapeutics worth $4.01M as of Q2 2026.
BNP Paribas Financial Markets bought 225,854 Summit Therapeutics shares in Q2 2026, an estimated $4.01M.
Summit Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2268 holding.
BNP Paribas Financial Markets first reported a position in Summit Therapeutics in Q3 2022 and has held it in 8 quarters since.
BNP Paribas Financial Markets's Summit Therapeutics position peaked at $21.2M in Q1 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.